Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Alcobra Ltd. (ADHD) to Contact the Firm

ARCT

NEW YORK, Dec. 17, 2014 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alcobra Ltd. ("Alcobra" or the "Company") (Nasdaq:ADHD) of the January 19, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Alcobra and certain officers of the Company.

A complaint has been filed in the United States District Court for the Southern District of New York on behalf of all persons who purchased Alcobra securities between March 28, 2014 and November 14, 2014 (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its statements concerning its business, operations, and prospects.

Specifically, the action alleges that during the Class Period, Alcobra misrepresented and/or failed to disclose that (i) until patients were removed from the Phase III study of Alcobra's product MDX, MDX failed to show a statistical benefit compared to placebos; and (ii) the Company had presented its analyses inconsistently.

On November 17, 2014, Alcobra announced that the topline data results of the Phase III trial of MDX in adult subjects with ADHD did not show a statistically significant outcome.

Following this news, the price of Alcobra's stock declined by $0.23 per share, or over 5%, to close on November 17, 2014 at $3.45 per share.

Request more information now by clicking here: www.faruqilaw.com/ADHD. There is no cost or obligation to you.

Take Action

If you invested in Alcobra common stock or options between March 28, 2014 and November 14, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/ADHD. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Alcobra's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT: FARUQI & FARUQI, LLP
         369 Lexington Avenue, 10th Floor
         New York, NY 10017
         Attn:  Richard Gonnello, Esq.
         rgonnello@faruqilaw.com
         Telephone: (877) 247-4292 or (212) 983-9330

Faruqi & Faruqi LLP Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today